Mutations in chromatin regulator (CR) genes occur frequently across human cancers and have been linked to increased tumor mutational burden (TMB) and enhanced response to immune checkpoint inhibitors (ICIs). This study examined CR mutation–outcome relationships at the level of individual cancer types using both discovery and independent validation cohorts. The analysis resolved cancer-specific sets of CR genes whose mutations were associated with improved survival following ICI treatment and also highlighted recurrent CRs and co-occurring mutation patterns that correlated with further survival benefit.
The authors analyzed publicly available, de-identified cancer genomics data drawn from previously published datasets and projects. All data used are available through cBioPortal for Cancer Genomics, including the GENIE resource. Because the study relied exclusively on publicly available de-identified datasets, no additional ethics approval or patient consent was required. The manuscript is posted as a preprint and has not undergone peer review.
Ten cancer types were explicitly profiled in the study: colorectal cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, bladder cancer, esophagogastric cancer, pancreatic adenocarcinoma, prostate cancer, and breast cancer. For each cancer type the authors identified CR genes whose mutations correlated with improved post-ICI survival in both discovery and independent validation cohorts when available.
Within each cancer type the analysis resolved a distinct set of CR genes for which mutations were associated with favorable survival after immune checkpoint therapy. The authors refer to these as pro-survival CR genes. The selection and validation across cohorts indicate that individual cancers display unique CR mutation–outcome signatures rather than a single universal CR set predicting benefit in all tumors.
The study emphasizes that observed associations are cancer type specific: a CR gene associated with improved survival in one tumor type may show a different effect size or no significant association in another. Details on the specific genes identified per cancer type and the analytic thresholds used were reported in the full manuscript and supplementary material available with the preprint.
Beyond cancer-specific findings, the authors identified a subset of recurrent CR genes whose mutations were associated with improved ICI outcomes across multiple cancer types. Although these recurrent associations were observed across several tumor types, the magnitude of the survival association varied between cancers. The presence of recurrent CRs suggests shared biology linking chromatin regulation, mutational processes, and immunotherapy response in diverse tumor contexts.
The analysis found that co-occurrence of mutations in two or more CR genes correlated with greater improvement in survival following ICI therapy than mutation in a single CR gene alone. This pattern indicates potential additive or synergistic effects of multiple CR alterations on tumor phenotype, mutational landscape, and responsiveness to immune checkpoint blockade. The authors note that several individual CR genes showed particularly robust associations with favorable outcomes, while combined CR mutation patterns provided additional stratification of survival benefit.
Across the profiled cancer types, patient groups defined by CR alterations consistently displayed higher tumor mutational burden (TMB) compared with their corresponding CR-unaltered groups. This consistent enrichment of TMB among CR-altered tumors supports a mechanistic link in which CR mutations may contribute to increased neoantigen load or genomic instability that, in turn, enhances susceptibility to immune checkpoint therapy. The study positions the CR–TMB relationship as a likely contributor to the observed survival associations.
Using transcriptomics-based deconvolution, the authors evaluated differences in the tumor microenvironment (TME) associated with CR mutation status. The deconvolution analyses revealed cancer-type-specific differences in immune and stromal cell composition linked to CR alterations. These TME differences provide additional context for how CR mutations may influence ICI response beyond TMB, suggesting that CR-altered tumors can display distinct immune infiltration or microenvironmental states depending on cancer type.
All analyzed data are publicly available through cBioPortal (http://www.cbioportal.org and https://genie.cbioportal.org). The authors declared no competing interests. No dedicated research funding was reported; personnel salaries were supported by Fingerprint Diagnostics LLC and Zan Mitrev Clinic. The manuscript conforms to appropriate ethical guidelines for studies using publicly available de-identified data.
The findings demonstrate that CR mutation patterns are both cancer-specific and recurrent across tumor types and that these patterns associate with increased TMB and improved survival after ICI therapy. Co-occurring CR mutations may identify patients with the greatest magnitude of benefit. These results could inform biomarker development linking chromatin regulation, mutational processes, and immunotherapy response.
Limitations include that the work is reported as a preprint and has not been peer reviewed; the summary here reflects the content presented in the source and does not substitute for formal validation. Specific effect sizes, statistical methods, and the lists of identified CR genes per cancer type are reported in the full manuscript and supplementary material available with the preprint. Further validation in independent prospective cohorts and functional studies would be required before clinical implementation.
Together, the study adds evidence that chromatin regulator mutations interact with tumor mutational load and the tumor microenvironment in ways that are relevant to ICI responsiveness, emphasizing both the cancer-specific and shared genomic features that may underlie immunotherapy benefit.